Cell Biosciences to launch new tech with $10M
Cell Biosciences announced that it’s just brought in $10 million in a third round of funding to launch its new protein analysis technology used to track cellular pathways. It plans to sell its products to labs and research institutions that are developing medications and chemical diagnostics for cancer, diabetes and other diseases.
The Palo Alto, Calif. company has scheduled the launch for its new technology at the end of this month. A previous version of the product has been on the market since 2007, but this update is said to be cheaper to make, more compact and faster to use.
The recent round of financing was led by Wellcome Trust and included Domain Associates, Latterell Venture Partners, Mitsui Ventures, Novo A/S, Royal Bank of Canada and Vertical Group. Cell has now raised $50.5 million to date.
Next Story: Phoebe’s Cupcakes eats up $1.5M from Ascent
Previous Story: Ditched by potential parents, Digg grows up on its own
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.